Volanesorsen for treating familial chylomicronaemia syndrome

mechanism of action represents a step change in managing FCS. The patient experts explained that having a treatment available would give people with the condition hope, both for themselves and for family members and carers. Conclusion 4.38 The committee recognised that FCS is a rare, serious and, at times, life- threatening condition that can substantially affect the lives of patients, and their families and carers. The committee understood that there is an unmet need for an effective treatment. After considering all available evidence, and the opinions of the clinical and patient experts, the committee agreed that volanesorsen was associated with improved TG levels and likely reduced the risk of clinical outcomes such as AP and abdominal pain in the short term. It concluded that volanesorsen would likely provide some long-term benefits too. However, this was associated with substantial uncertainty, particularly at the licensed dose, which was not used in the clinical trial that provided the evidence base for decision making. 4.39 Overall, the committee considered that the available evidence suggested that volanesorsen could provide important clinical benefits. It considered that there were uncertainties in interpreting the evidence and the company's assumptions in the model, especially around volanesorsen's protective effect on
